Hanneke Schuitemaker Nederlands viroloog en onderzoeker
Schuitemaker, Hanneke 1964-
VIAF ID: 283934140 (Personal)
Permalink: http://viaf.org/viaf/283934140
Preferred Forms
4xx's: Alternate Name Forms (6)
Works
| Title | Sources |
|---|---|
| A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism |
|
| An HIV-1 antibody from an elite neutralizer implicates the fusion peptide as a site of vulnerability |
|
| HIV-1 envelope diversity 1 year after seroconversion predicts subsequent disease progression |
|
| HIV-1 envelope glycoprotein resistance to monoclonal antibody 2G12 is subject-specific and context-dependent in macaques and humans |
|
| HIV-1 envelope glycoprotein signatures that correlate with the development of cross-reactive neutralizing activity. |
|
| HIV-1 replication fitness of HLA-B*57/58:01 CTL escape variants is restored by the accumulation of compensatory mutations in gag |
|
| HIV-1 seroreversion in an HIV-1-seropositive patient treated during acute infection with highly active antiretroviral therapy and mycophenolate mofetil |
|
| HIV-1 Subtype C Gag-Specific T-Cell Responses in Relation to Human Leukocyte Antigens in a Diverse Population of HIV-Infected Ethiopians |
|
| HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy |
|
| HIV tropism and CD4+ T-cell depletion |
|
| Host genetic factors in the clinical course of HIV-1 infection: chemokines and chemokine receptors |
|
| Identification of Genes Whose Expression Profile Is Associated with Non-Progression towards AIDS Using eQTLs |
|
| Identification of Sequential Viral Escape Mutants Associated with Altered T-Cell Responses in a Human Immunodeficiency Virus Type 1-Infected Individual |
|
| Immunization with recombinant macaque major histocompatibility complex class I and II and human immunodeficiency virus gp140 inhibits simian-human immunodeficiency virus infection in macaques. |
|
| Immunogenicity of Stabilized HIV-1 Envelope Trimers with Reduced Exposure of Non-neutralizing Epitopes |
|
| Impact of CCR5 Delta32/+ deletion on herpes zoster among HIV-1-infected homosexual men |
|
| Impact of CCR5delta32 host genetic background and disease progression on HIV-1 intrahost evolutionary processes: efficient hypothesis testing through hierarchical phylogenetic models |
|
| Impact of host cell variation on the neutralization of HIV-1 in vitro |
|
| In vivo evolution of X4 human immunodeficiency virus type 1 variants in the natural course of infection coincides with decreasing sensitivity to CXCR4 antagonists |
|
| An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model |
|
| Incomplete Neutralization and Deviation from Sigmoidal Neutralization Curves for HIV Broadly Neutralizing Monoclonal Antibodies |
|
| Increased sensitivity to CD4 binding site-directed neutralization following in vitro propagation on primary lymphocytes of a neutralization-resistant human immunodeficiency virus IIIB strain isolated from an accidentally infected laboratory worker |
|
| Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine |
|
| International network for comparison of HIV neutralization assays: the NeutNet report II |
|
| Isolation and propagation of HIV-1 on peripheral blood mononuclear cells |
|
| Lack of evidence for an association between a polymorphism in CX3CR1 and the clinical course of HIV infection or virus phenotype evolution |
|
| Longer V1V2 region with increased number of potential N-linked glycosylation sites in the HIV-1 envelope glycoprotein protects against HIV-specific neutralizing antibodies |
|
| Longitudinal analysis of early HIV-1-specific neutralizing activity in an elite neutralizer and in five patients who developed cross-reactive neutralizing activity |
|
| Loss of HIV-1-derived cytotoxic T lymphocyte epitopes restricted by protective HLA-B alleles during the HIV-1 epidemic |
|
| Low incidence of HIV-1 superinfection even after episodes of unsafe sexual behavior of homosexual men in the Amsterdam Cohort Studies on HIV Infection and AIDS |
|
| Low-level CD4+ T cell activation is associated with low susceptibility to HIV-1 infection |
|
| Low level of HIV-1 evolution after transmission from mother to child |
|
| Low levels of human immunodeficiency virus type 1 DNA in high-risk seronegative men |
|
| The major genetic determinants of HIV-1 control affect HLA class I peptide presentation |
|
| Mini-hemagglutinin vaccination induces cross-reactive antibodies in pre-exposed NHP that protect mice against lethal influenza challenge. |
|
| Molecular evolution of human immunodeficiency virus type 1 upon transmission between human leukocyte antigen disparate donor-recipient pairs |
|
| Multicohort genomewide association study reveals a new signal of protection against HIV-1 acquisition |
|
| Multiple-cohort genetic association study reveals CXCR6 as a new chemokine receptor involved in long-term nonprogression to AIDS. |
|
| Natural controlled HIV infection: preserved HIV-specific immunity despite undetectable replication competent virus |
|
| Naturally HIV-1 seroconverters with lowest viral load have best prognosis, but in time lose control of viraemia |
|
| The Neutralizing Antibody Response in an Individual with Triple HIV-1 Infection Remains Directed at the First Infecting Subtype |
|
| Neutralizing antibody responses induced by HIV-1 envelope glycoprotein SOSIP trimers derived from elite neutralizers |
|
| No treatment versus 24 or 60 weeks of antiretroviral treatment during primary HIV infection: the randomized Primo-SHM trial |
|
| A nonprogressive clinical course in HIV-infected individuals expressing human leukocyte antigen B57/5801 is associated with preserved CD8+ T lymphocyte responsiveness to the HW9 epitope in Nef |
|
| Novel strategy for the selection of human recombinant Fab fragments to membrane proteins from a phage-display library |
|
| PER.C6 |
|
| PER.C6(®) cells as a serum-free suspension cell platform for the production of high titer poliovirus: a potential low cost of goods option for world supply of inactivated poliovirus vaccine |
|
| Persistence of viral HLA-DR- CD4 T-cell reservoir during prolonged treatment of HIV-1 infection with a five-drug regimen. |
|
| Phenotypic and genotypic comparisons of CCR5- and CXCR4-tropic human immunodeficiency virus type 1 biological clones isolated from subtype C-infected individuals |
|
| Polymorphism in HIV-1 dependency factor PDE8A affects mRNA level and HIV-1 replication in primary macrophages. |
|
| Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load |
|
| Prediction of residual time to AIDS and death based on markers and cofactors |
|
| The presence of CXCR4-using HIV-1 prior to start of antiretroviral therapy is an independent predictor of delayed viral suppression |
|
| The presence of the Trim5alpha escape mutation H87Q in the capsid of late stage HIV-1 variants is preceded by a prolonged asymptomatic infection phase |
|
| Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study |
|
| Probability of N332 glycan occupancy on HIV-1 gp120 modulates sensitivity to broadly neutralizing antibodies |
|
| R5 human immunodeficiency virus type 1 infection of fetal thymic organ culture induces cytokine and CCR5 expression |
|
| Rapid escape from preserved cross-reactive neutralizing humoral immunity without loss of viral fitness in HIV-1-infected progressors and long-term nonprogressors |
|
| Recombinant low-seroprevalent adenoviral vectors Ad26 and Ad35 expressing the respiratory syncytial virus (RSV) fusion protein induce protective immunity against RSV infection in cotton rats |
|
| Reconstructing the Dynamics of HIV Evolution within Hosts from Serial Deep Sequence Data |
|
| Recovery of viremic control after superinfection with pathogenic HIV type 1 in a long-term elite controller of HIV type 1 infection |
|
| Rising HIV-1 viral load set point at a population level coincides with a fading impact of host genetic factors on HIV-1 control |
|
| The role of innate APOBEC3G and adaptive AID immune responses in HLA-HIV/SIV immunized SHIV infected macaques |
|
| Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19 |
|
| Safety and immunogenicity of Ad26 and MVA vaccines in acutely treated HIV and effect on viral rebound after antiretroviral therapy interruption |
|
| Safety and Immunogenicity of Novel Adenovirus Type 26- and Modified Vaccinia Ankara-Vectored Ebola Vaccines: A Randomized Clinical Trial |
|
| Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults |
|
| Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study |
|
| Screening low-frequency SNPS from genome-wide association study reveals a new risk allele for progression to AIDS |
|
| Selected HIV-1 Env trimeric formulations act as potent immunogens in a rabbit vaccination model |
|
| Short communication: No detrimental immunological effects of mycophenolate mofetil and HAART in treatment-naive acute and chronic HIV-1-infected patients |
|
| Similar Epitope Specificities of IgG and IgA Antibodies Elicited by Ad26 Vector Prime, Env Protein Boost Immunizations in Rhesus Monkeys |
|
| Single nucleotide polymorphism in gene encoding transcription factor Prep1 is associated with HIV-1-associated dementia |
|
| Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques |
|
| Susceptibility of recently transmitted subtype B human immunodeficiency virus type 1 variants to broadly neutralizing antibodies |
|
| Synthetic virus seeds for improved vaccine safety: Genetic reconstruction of poliovirus seeds for a PER.C6 cell based inactivated poliovirus vaccine |
|
| T cell line passage can select for pre-existing neutralization-sensitive variants from the quasispecies of primary human immunodeficiency virus type-1 isolates |
|
| Time-measured phylogenies of gag, pol and env sequence data reveal the direction and time interval of HIV-1 transmission |
|
| A Universal Approach to Optimize the Folding and Stability of Prefusion-Closed HIV-1 Envelope Trimers. |
|
| Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys |
|
| Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection |
|
